Literature DB >> 32357083

Subjective Quality of Vision in Evaporative Dry Eye Patients After Intense Pulsed Light.

Qingxia Fan1, Emmanuel Eric Pazo1, Yue You1, Can Zhang1, Chenguang Zhang1, Ling Xu1, Wei He1.   

Abstract

Background and objective: Intense pulsed light (IPL) improves visual and clinical symptoms of dry eye disease and helps improve meibomian gland (MG) function thereby positively contributing to the tear lipid layer, a major component for a normal tear film physiology. The objective of this study was to assess the effectiveness of IPL in moderate to severe evaporative dry eye (DE) owing to meibomian gland dysfunction (MGD) on the subjective quality of vision (QOV).
Methods: This is a prospective, open-label study; patients with moderate to severe evaporative DE owing to MGD were consecutively enrolled and underwent two IPL treatment sessions at 3-week intervals. Clinical assessments included: Ocular Surface Disease Index (OSDI) and QOV questionnaires, noninvasive tear breakup time (NITBUT), interferometric fringe pattern as determined by tear film lipid layer (TFLL) quality, lid margin abnormalities, corneal fluorescein staining (CFS), conjunctival hyperemia (CH) redness score, MG (evaluated with a slit-lamp microscope), best-corrected visual acuity, endothelial cell count, and intraocular pressure were conducted at pretreatment, days 21 and 42 after IPL treatment.
Results: A total of 128 eyes of 64 patients (39 women, 25 men; mean age 36.09 ± 11.13 years) with moderate to severe DE owing to MGD consecutively received IPL treatment at days 1 and 21. OSDI (p < 0.05), QOV (p < 0.05), NITBUT (p < 0.05), TFLL score (p < 0.05), and MG quality and expressibility (p < 0.05) improved significantly at day 42, whereas CFS and CH showed minor not significant improvements (p > 0.05) at day 42 of assessment. Conclusions: IPL treatment reduced the severity of DE symptoms and improved the overall tear film stability in patients with moderate to severe evaporative DE owing to MGD. In addition, visual complaints experienced by DE patients secondary to MGD significantly decreased.

Entities:  

Keywords:  Intense pulsed light devices (IPL)/therapy; OSDI; dry eye; quality of vision

Mesh:

Year:  2020        PMID: 32357083     DOI: 10.1089/photob.2019.4788

Source DB:  PubMed          Journal:  Photobiomodul Photomed Laser Surg        ISSN: 2578-5478


  5 in total

1.  Reliability of Chinese web-based ocular surface disease index questionnaire in dry eye patients: a randomized, crossover study.

Authors:  Xin-Mei Zhang; Lan-Ting Yang; Qing Zhang; Qing-Xia Fan; Can Zhang; Yue You; Chen-Guang Zhang; Tie-Zhu Lin; Ling Xu; Salissou Moutari; Jonathan E Moore; Emmanuel E Pazo; Wei He
Journal:  Int J Ophthalmol       Date:  2021-06-18       Impact factor: 1.779

2.  Management of Post-LASIK Dry Eye with Intense Pulsed Light in Combination with 0.1% Sodium Hyaluronate and Heated Eye Mask.

Authors:  Yi Wu; Ling Xu; Yilin Song; Qing Zhang; Guanghao Qin; Lanting Yang; Jinfei Ma; Christoph Palme; Jonathan E Moore; Emmanuel Eric Pazo; Wei He
Journal:  Ophthalmol Ther       Date:  2021-11-06

3.  Screening Evaporative Dry Eyes Severity Using an Infrared Image.

Authors:  Qing Zhang; Yi Wu; Yilin Song; Guanghao Qin; Lanting Yang; Sumeet Singh Talwar; Tiezhu Lin; Gagan Deep Singh Talwar; Hongda Zhang; Ling Xu; Jonathan E Moore; Emmanuel Eric Pazo; Wei He
Journal:  J Ophthalmol       Date:  2021-08-24       Impact factor: 1.909

4.  Intense pulsed light-based treatment for the improvement of symptoms in glaucoma patients treated with hypotensive eye drops.

Authors:  Jose Maria Martinez-de-la-Casa; Carlos Oribio-Quinto; Almudena Milans-Del-Bosch; Pilar Perez-Garcia; Laura Morales-Fernandez; Javier Garcia-Bella; Jose Manuel Benitez-Del-Castillo; Julian Garcia-Feijoo; David P Piñero
Journal:  Eye Vis (Lond)       Date:  2022-04-01

5.  Prevalence of symptomatic dry eye in breast cancer patients undergoing systemic adjuvant treatment: A cross-sectional study.

Authors:  Jinfei Ma; Emmanuel Eric Pazo; Zihao Zou; Feng Jin
Journal:  Breast       Date:  2020-08-05       Impact factor: 4.380

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.